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CONNECTING STRUCTURAL CHANGES TO CELL TRANSFORMATION PATTERNS IN THE CANINE 
DEGENERATIVE MITRAL VALVE 
 
 Degenerative mitral valve disease (DMVD) is a significant problem in the canine 
population and also affects humans. Recent studies have provided insight into molecular and 
cellular mechanisms that likely contribute to disease progression. Better understanding of the 
cellular processes that mediate the degenerative process could lead to treatments that prevent 
or slow this degeneration benefiting both canine and human patients. Structural changes to 
degenerative valves such as nodules, leaflet thickening, increased opacity, loss of elasticity and 
loss of valve architecture have been well documented. Abnormal cell transformation patterns 
such as the transformation of valvular interstitial cells to activated myofibroblasts have been 
characterized in degenerative mitral valve tissue, as well as other irregular cell behavior such as 
the overproduction of glycosaminoglycan and matrix remodeling factors that have become  
hallmarks of the disease. Despite these important discoveries, much remains unknown about 
cell signaling in degenerative mitral valve disease and how cell activity changes a normal valve 
to the diseased phenotype. An overarching hypothesis of this study is that investigating 
signaling mechanisms active in degenerative valves could provide insight into cellular processes 
mediating the disease. A specific hypothesis that emerged from initial results is  that 
endothelial to mesenchymal transition (EndMT), a process important in valvulogenesis, could 
be active in degenerative mitral valves. 
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 The first goal of this study was to compare protein abundance in degenerative and 
normal mitral valves to determine if there exists previously unidentified signaling molecules 
that could be initiating or perpetuating the cellular transformations and abnormalities present 
in DMVD. The second goal was to investigate these proteins using immunohistochemistry to 
characterize their activity in the tissue matrix and show evidence of their contribution to 
structural changes of the valve. The first goal was accomplished by doing a targeted microarray 
analysis of signaling proteins comparing their relative abundance in normal and degenerative 
mitral valves. This analysis yielded an increased abundance of signaling proteins that have been 
associated with EndMT. The second goal was accomplished by immunohistochemistry to 
determine the spatial distribution of selected proteins from the microarray analysis with 
markers of endothelial cells and mesenchymal cells (activated myofibroblasts). 
 Targeted microarray analysis of signaling proteins revealed increased abundance of 18 
proteins including the growth factor HB-EGF, its partner molecule ADAM17, and the cell 
adhesion molecule integrin β3, all possible mediators of EndMT (Chapter 4). 
Immunohistochemistry studies demonstrated the presence of cells positive for the endothelial 
marker CD31 within the valve interstitum. These CD31 positive cells co-localized with areas of 
myofibroblast transformation in degenerative valves identified by positive staining for α-
smooth muscle actin (αSMA). Expression of signaling proteins including HB-EGF and ADAM17 
also co-localized to these areas (Chapter 5). In conclusion, these results support active EndMT 
in canine degenerative mitral valves. EndMT could be contributing to the formation of high 
cellular density myofibroblast transformation which has been postulated to mediate mitral 
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Degenerative mitral valve disease (DMVD) is a significant health concern for many dogs. 
It often presents in older, smaller dogs, and its rate of progression can vary. Studying cellular 
changes apparent in degenerative valves increases our understanding of this common disease 
in both human and canine patients. Several patterns consistently seen in diseased valves have 
been identified, including overabundance of GAG, aggregation of αSMA positive cells, 
breakdown of collagen and elastin organization and dissolution of the normal stratification of 
the valve cells. Some patterns such as serotonin signaling have been implicated as causes of 
these degenerative changes, but overall cellular signaling in mitral valve cells is complex and 
still under investigation. To gain a more complete understanding of the disease, the present 
study began with a protein array which sought to identify proteins whose distributions varied in 
the diseased state and therefore recognize potential signaling cascades that contribute to 
degeneration. After studying the results of this initial array and comparing the significant 
proteins to previous studies and hypotheses about cellular change in DMVD, the hypothesis 
that endothelial to mesenchymal cell transformation, or EndMT, was occurring was formulated. 
EndMT is a specialized from of the boarder cellular mechanism of epithelial-to-mesenchymal 
transformation (EMT) which plays a prominent role during development and has an emerging 
role in a variety of diseases including cancer, inflammation, and degenerative diseases. This 
hypothesis could explain the increased cell density and modification of cell type found in areas 
of active disease and would also concur with theories that developmental processes are being 
re-activated in other degenerative valve disease. To test this hypothesis a marker of endothelial 
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cells, the protein CD31, also known as PECAM-1, was targeted with immunohistochemistry 
techniques to identify the location of endothelial cells in valve tissue. In conjunction with this 
marker, other significant proteins from the array were studied to determine if they co-localized 
with each other and with αSMA, which would indicate they play a role in the cellular 
transformation processes. Overall, determining the location in diseased tissue of these 
molecules of interest and comparing this information to healthy tissue will lead to a better 







Degenerative mitral valve disease (DMVD), also known as myxomatous mitral valve 
disease, is the most common heart disease observed in dogs.1 Estimates place the number of 
dogs affected in the United States between 3 and 7 percent of the population, correlating to 2.3 
to 5.3 million individuals. This prevalence is about ten times higher than that of DMVD in 
humans1, where it is still a major health concern, as it the most common cause of mitral 
regurgitation2. Because of similarities in its presentation and progression, research on canine 
mitral valve disease is also relevant to humans patients with the same disease3-4. DMVD is age 
related, progressive and yields a thickened, less elastic, nodular phenotype with an impaired 
ability to close properly that leads to regurgitation and heart remodeling. Without surgical 
intervention to repair or replace the valve, eventually the increased workload placed on the left 
ventricle by regurgitating flow overcomes the heart’s ability to compensate, leading to heart 
failure. While the primary causes of DMVD are incompletely understood, in some dog breeds it 
appears to have a genetic component5, it correlates positively with age6 and negatively with 
size7, and it is associated with other conditions such as hypertension8. Many cellular 
mechanisms present in the disease progression have been identified, but none yet seem to 
explain all aspects of the degenerative and phenotypic changes that exist in diseased valve 
tissues. To understand the causes of DMVD, it is important to investigate the changes and 




Tissue structure and morphology 
Healthy mitral valve tissue is composed of three principal layers, the atrialis, the 
spongiosa, and the fibrosa which each contribute to the valve’s ability to function properly. The 
atrialis, the layer facing the left atrium when the valve is closed, contains radially oriented 
elastin fibers which allow the valve to stretch as it opens and closes and encounters the high 
pressures of the left ventricle9. The fibrosa, which faces the left ventricle when the valve is 
closed, contains collagen fibers which provide structural strength to the valve leaflet when it is 
closed during ventricular systole10. The spongiosa exists between the atrialis and fibrosa, and is 
primarily composed of hydrated proteoglycan (PG) and glycosaminoglycan (GAG) which are 
thought to lubricate and provide support for the atrialis and fibrosa layers as they move with 
respect to each other during valve flexure.11  
Mitral valves exhibiting a degenerative (diseased) phenotype have some very distinct 
changes in their cellular structure. Diseased valves are commonly known to show an increase in 
both GAG and αSMA, and a loss of proper valve architecture where the layers of atrialis, 
spongiosa, and fibrosa become intermixed12(as in Figure 2.1). GAG content in degenerative 
valves can be increased by 30% to 150% and may contribute to mechanical weakness of the 
valve13. Interestingly, a study by Tamura et al. found that “the presence of excessive amounts of 
proteoglycans may interfere with the normal assembly of collagen and elastic fibers”14. This 
interference may explain the increased weakness and decreased distensibility of degenerative 
valves. Collagen fiber disorganization and disruption, recognized by King et al. (1982) is 




Figure 2.1 Photomicrograph of a Movat Stained Degenerative Canine Mitral Valve  
Figure 2.1 is a photomicrograph of a cross section of a degenerative valve stained with the 
Movat pentachrome procedure. To the far right (proximal end), normal valve layers are 
visible. The elastin fibers are stained black, collagen is stained yellow, and GAG is stained 
blue. As the valve thickens towards its distal end (left side), GAG becomes much more 
prominent and both collagen and elastin fibers appear less organized, demonstrating the loss 











 In addition to this elastin and collagen dysregulation, valvular interstitial cells begin to 
express catabolic enzymes, such as matrix metalloproteinases (MMPs), in the diseased state 
which degrade the extracellular matrix12. This causes matrix remodeling which changes the 
proper stratification of the layers, leading to abnormalities in the valve architecture. These 
weakened valve leaflets do not close properly or are forced open when they should be closed 
during ventricular systole, resulting in a regurgitant jet of blood flow back into the atrium. This 
backwards blood flow forces the heart to work harder in order to obtain the same amount of 
forward flow out the aorta to the body.  
Disease initiation and progression and the roles of serotonin, αSMA, and TGFβ 
As the heart generates more pressure to fulfill the body’s need for oxygenated blood, 
the already compromised valve is subjected to this increased pressure. Accordingly, valve tissue 
will sense this abnormal stress and strain and increase ECM remodeling. Studies show that 
valve cells exposed to increased strain in culture respond by escalating expression of αSMA, 
serotonin, MMPs, and GAG synthetic enzymes.15-16 This indicates that mechanoreceptors on 
valve cells are sensitive to cyclic tensile strain and respond by altering protein synthesis in a 
pattern consistent with MMVD. Besides causing diseased valves to degenerate further, this 
mechanism of progression may be responsible for the initiation of valve disease in hypertensive 
individuals, as high blood pressure has been shown to be associated with an increased risk of 
DMVD in humans.8 
However, initiating mechanisms and causes of the disease are still not fully understood. 
Hypertension and age related tissue weakening are accepted contributing factors but do not 
account for the total prevalence of DMVD in dogs and humans, especially in younger animals 
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and certain breeds. Serotonin signaling may be an important mechanism involved in DMVD, as 
Disatian et al. found that diseased canine and human mitral valves exhibited increased 
serotonin synthetic enzymes and decreased transporters necessary for serotonin breakdown.17 
This study also shows increased TGFβ receptors and phosphorylated ERK ½ which may be 
activated by the serotonin mechanism. These molecules are involved in activating transcription 
factors which influence the cell to undergo phenotype transformation, proliferation, and 
stimulate matrix remodeling. TGFβ expression in canine mitral valves has been examined in 
depth by Aupperle et al. and seems to be a contributing factor to disease phenotype proteins 
such as αSMA.18 While the serotonin hypothesis (Figure2.2) for the initiation of DMVD is very 
promising, the causes and downstream effects of this signaling still need more investigation. 
Overall, the initiation and progression of DMVD is a multifaceted and complicated biochemical 
process. There does not seem to be one clear answer as to the cause, but investigation of 
cellular signaling has contributed to our knowledge of what diseased cells express and how they 







Figure 2.2 The Serotonin Hypothesis 
Figure 2.2 illustrates the serotonin hypothesis of DMVD initiation. Principle molecules 
involved in this process include the serotonin transporter, SERT, the serotonin receptor 5-
HT2BR, and the serotonin degrading enzyme MAO. Studies of these molecules indicate that 









Previous studies have identified patterns of interstitial cell phenotype transformation20, 
changes in cell density21, and changes in protein expression in degenerative valve tissue22. One 
example of this is the change from a normal or quiescent fibroblastic type interstitial cell to an 
“activated myofibroblast” which expresses catabolic enzymes such as MMPs implicated in the 
pathological remodeling process present in diseased valves21. The activated myofibroblast cell 
is identified by the expression of αSMA, which increases dramatically in diseased valves and 
positively correlates with severity23. Besides simply increasing however, the distribution of this 
cytoskeletal protein also varies. Instead of only appearing in a thin layer of the atrialis which 
occurs in normal valves, αSMA positive cells are present throughout the atrialis and into the 
spongiosa and seem to form clusters21 .This αSMA expression pattern in degenerative valves 
usually correlates with distinct nodules and is considered a good identifier of areas of active 










Figure 2.3 αSMA Immunohistochemistry Stained Canine Degenerative Mitral Valve 
The dark brown staining on this photomicrograph of a valve with DMVD indicates the 
presence of αSMA (alpha smooth muscle actin). Clearly, the positive cells form a nodule in 








As mentioned previously, TGFβ, a cytokine involved in ECM regulation, plays a 
significant role in DMVD. In cultured valvular interstitial cells TGFβ-1 contributed to 
myofibroblast transformation, linking it to the expression of αSMA in valve cells24. Besides this 
role, TGFβ has other widespread effects in the body that contribute to many diverse outcomes, 
including ECM management, inhibiting cell proliferation, immune function, and mesenchymal 
cell transformation. Examples of processes where TGFβ signaling is important would be in 
wound healing, fibrosis, cancer progression or suppression, and embryonic development. In 
these processes TGFβ often functions by causing cells to undergo epithelial to mesenchymal cell 
transition, or EMT25. This mechanism involves two TGFβ receptors, I and II, which transmit the 
signal initiated by TGFβ binding and activate canonical and non-canonical pathways. The 
canonical pathway activates the molecules Smad 2/3 which bind Smad 4 and this complex 
enters the nucleus and acts as a transcription factor, changing the activity of the cell25. The non-
canonical pathway uses a variety of signaling cascades, including Erk, JNK, and MAP kinases 
which play important roles in the initiation of EMT26 . 
Developmental pathways  
EMT is a programmed cellular process which involves the transformation of organized 
epithelial cells into motile mesenchymal cells by the removal of anchoring proteins and the 
restructuring of the actin cytoskeleton25. EndMT is a variation of this process wherein endothelial 
cells transform. Of particular interest is TGFβ’s role in contributing to EMT in cardiac valve 
development, along with BMP and Notch signaling27. The BMP ligands are members of the TGFβ 
superfamily of signaling molecules. BMP signaling is the first step in the commencement of EMT 
in the developing heart valve, followed by Notch signaling. Notch is a single transmembrane 
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receptor that when bound to its ligand exposes an active site which a disintegrin and 
metalloproteinase (ADAM17 or ADAM10) will cleave and the remaining portion will be 
endocytosed, migrate to the nucleus, and cause its effects, including stimulating multiple genes 
that are present in EMT as well as production of αSMA27. The effects of BMP, Notch, and 
continued TGFβ signaling support the cellular changes taking place by engaging in “cross talk” 
as the endothelial cells begin to form the mesenchymal cells of the developing heart valve28. 
 Both BMP and TGFβ are involved in the regulation of Sox-9 in chondrogenesis. 
Chondrogenesis is believed to be taking place in diseased mitral valves, as shown by the 
presence of type II collagen, a product of the process, and Sox 9, a transcription factor involved 
in initiating it29. The presence of these chondrogenic factors detected in diseased valves by IHC 
suggests that this pathway is active in degenerative valve disease. Interestingly, other 
developmental processes have been documented in valve diseases, specifically osteogenic 
pathways documented in calcific aortic valve disease30. The presence of indicators of 
chondrogenesis and osteogenesis in diseased heart valves has lead to the hypothesis that 
reactivation of developmental pathways may be a primary cause of disease31. Another piece of 
evidence supporting this theory would be the differing distribution of αSMA. In a study by 
Rabkin-Aikawa et al.,32 the percent of VICs expressing αSMA in fetal hearts was about 60%, 
whereas in normal adults it was only 2.5%. In degenerative valves, however, the percentage of 
VICs expressing αSMA rose to approximately 36%, indicating a similar activated myofibroblast 
cell phenotype to the fetal valves. After considering these similarities it makes sense that 
examining the signaling systems involved in early valve development may lead to a greater 
understanding of the degenerative processes of the diseased state. Other cell processes and 
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patterns causing the changes found in the disease may be discovered by further investigation of 
embryonic signaling mechanisms.  
An embryonic pathway that has been studied in valve development but not in disease is 
that of heparin binding epidermal growth factor (HB-EGF), its “sheddase” ADAM17 which is 
responsible for its release from the cell membrane, and its receptor, the epidermal growth 
factor receptor (EGFR).  ADAM17, also known as TACE, has been identified as the primary 
regulator of HB-EGF concentrations in valve development, as it cleaves pro-HB-EGF and 
releases it in an active form so that it can bind its receptor, the EGFR33. Knockout mice have 
shown that interference with this pathway leads to malformed valves34. This study also 
determined that HB-EGF was the most important ligand for the EGFR in valve developmental 
remodeling, which involves the establishment of the valve layers from the endothelial and 
mesenchymal cells.34 Another study found that “HB-EGF plays a positive role in the migratory 
capability of valve endothelial cells”35 further supporting its role in directing cells in valve 
development. Also, HB-EGF signaling is considered to be regulated by BMP signaling, therefore 
it functions as a secondary process taking place after the EMT initiating mechanisms described 





Figure 2.4 Valvular Morphogenesis from the Early Embryonic State to the Mature Heart 
Valve 
Figure 2.4 depicts how endothelial cells (blue line) migrate deeper into the cardiac cushion 
and transform into mesenchymal cells which then form the layers and structure of the adult 
valve. Much signaling is involved in this process and the fluid dynamics of blood passing 
through the heart also influences the development of the tissue. Figure inspired by a diagram 











Pathways related to valve mechanics 
Previous studies have found that HB-EGF to EGFR signaling is influence by both cyclic 
stretch37-39, and by increased pressure40. This finding relating mechanoreceptors to cell 
signaling changes has also been replicated in mitral valve studies which exert strain on valves in 
tissue studies and evaluate differential protein expression15,41. These studies show that proteins 
that are suggestive of degenerative disease can be induced in valves by subjecting them to 
increased stress and stretch loads, specifically cyclic tensile strain. Therefore even though the 
specific mechanosensors responsible for responding to these physical changes have not been 
identified, it is now accepted that increased cyclic strain can cause a DMVD phenotype. This 
may be the mechanism of initiation of DMVD in individuals with hypertension as discussed 
earlier, but it is not a complete explanation of the genesis of DMVD in all animals. Also, while 
the serotonin hypothesis is consistent with these findings,41 it does not explain specifically how 
TGFβ appears to cause degenerative changes. A more complete understanding of TGFβ’s 
method of causing cellular reactions may include its interactions with the other developmental 
pathways and as an initiator of EMT. Also, other signaling mechanisms influenced by 
mechanical input such as HB-EGF binding to EGFR may work simultaneously with TGFβ 
signaling, because in some instances, they lead to the same downstream molecule becoming 





Figure 2.5 TGFβ and EGFR Signaling 
This figure shows pathways of TGFβ and EGFR signaling. It highlights the common processes 
between EGFR, TGFβ and serotonin signaling, specifically the activation of ERK ½ 
(pp=phosphorylated) and the SMADs, and how these messengers lead to the production of 
effector molecules that change the cell’s behavior (such as MMPs, far right).  Figure inspired 








Other proteins that may be relevant to these signaling cascades include the integrins. 
Integrins are heterodimeric transmembrane proteins with a variety of cellular functions. In 
relation to TGFβ signaling, integrin αvβ3 has been shown to bind the TβRII portion of the TGFβ 
receptor and skew TGFβ’s affect on the cell from a growth arrest signal to a signal of EMT 
initiation42. This study also found that not only was this integrin expression tied to EMT, but “β3 
integrin expression appears essential for TGFβ stimulation of EMT”,42 further underlining its 
importance to this signaling pathway. In addition to this information, investigators also found 
that cells expressing integrin β3 significantly increased ERK½ activation after they were 
stimulated with TGFβ-1, highlighting the mechanism by which this signal is transmitted42. This 
study presents an explanation for the many other cases where integrin αvβ3 has been shown to 
be upregulated in EMT in cancers43-45. EMT induced through integrin αvβ3 has been studied44 as 
well as EMT as a process by which malignant tumor cells invade healthy tissue46. One way this 
happens is the cells in a tumor that are able to downregulate normal cell-cell attachment 
proteins, an early step in EMT, will have less contact inhibition on their growth rates. As these 
cells proliferate rapidly, they de-differentiate and accumulate mutations. As the pathways of 
EMT include both the loss of endothelial markers and the gain of motility factors, these 
cancerous cells have a higher chance of being able to invade local tissues or migrate to distant 
sites as metastases.  
Integrin αvβ3’s role in cell migration capability47 as well as its part in the EMT process 
seems to account for its presence in invasive cancers, and it may play a role in EMT in heart 





Figure 2.6 Integrin Influence on Signaling 
Figure 2.6 illustrates how integrins (pink) influence the signaling of TGFβ and EGFR because 
they are coupled to the respective receptors. Integrin roles in ECM-cytoskeletal interactions 
(far right) are a pathway by which mechanical forces influence cell signaling. Integrin β3’s 
interactions with TβRI and II change the course of TGFβ signaling. Figure inspired by a 











Cell density and transformation in the diseased valve 
A recent finding described by Disatian et al. is the increased cellularity present in 
degenerative valves. Her work showed that diseased valves have increased cell density, 
especially in the atrialis layer48 but increased cell division does not seem to be the cause of this 
result21 because Ki-67, a marker of active cell division was not found to be increased in diseased 
areas. These areas of increased cell density seem to produce, or at least colocalize with, the 
distinctive degenerative nodules and thickening. Two theories to explain the increased cell 
density were proposed, that there is decreased cell death in the area or that cells may be 
migrating from other areas to the points of disease. To determine the cause of this increased 
cellularity, another study investigating apoptosis in these areas was performed. This research 
used the TUNEL assay to examine the apoptosis pathway and found that "an anti-apoptosis 
mechanism does not explain the increase in cell density seen in canine myxomatous mitral 
valves"49. Also, data from other protein arrays shows an abundance of migratory proteins in 
degenerative valve tissue, indicating that cell migration is the more likely cause of the increased 
cell density22. 
The molecule CD31 also known as platelet endothelial cell adhesion molecule-1, is a 
specific identifier of endothelial cells, and has been used to study their location50. Endothelial 
cells of heart valves are subjected to strong mechanical forces such as shear stress and are 
often damaged in degenerative valves. A study by Corcoran et al. using electron microscopy 
observed denudation of endothelial cells on areas of degenerative valves presumably because 
of mechanical damage51. The remaining endothelial cells adjacent to these denuded areas 
showed an increase in microappendages which they suggest indicates protective and repair 
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responses. While this damage would seem to be caused by the increased stresses and pressures 
diseased valves face, these repair mechanisms may contribute to the worsening of the disease 
by causing the thickening which impairs the proper function of the valve. 
Whichever way the valve becomes damaged initially, discovering the cell mechanisms 
by which DMVD propagates is integral to developing a treatment or prevention for it. Studying 
markers for signaling cascades such as serotonin, TGFβ, and Notch are one way of trying to 
understand how and why the valve cells transform and begin to express MMPs, αSMA, and 
other proteins which directly cause the degenerative changes.  Perhaps altering these signals 
could alter the course of the disease as the valve becomes progressively more dysfunctional. 
After examining elements that the signaling molecules discussed above have in common as well 
as the hypothesis that developmental pathways are involved in degenerative disease, we 
decided to determine if EndMT occurs in degenerative valves. CD31 is the primary molecule of 
interest as it should indicate endothelial cell locations. If endothelial cells are detected 
migrating into deeper cell layers, then this would indicate that they are transforming and 
undergoing EndMT. Also, if this EndMT occurs at areas of the valve where activated 
myofibroblasts are expressing increased αSMA, then this would support the possibility that 
EndMT is responsible for increased cell density in diseased areas. Because TGFβ, the primary 
initiator of EMT, has already been shown to be increased in diseased valves, other signaling 
processes present in developmental EMT such as HB-EGF will also be studied, as well as 





Hypothesis and Objectives 
The hypotheses of this thesis were: 
Hypothesis 1: Differential protein expression in degenerative (myxomatous) mitral 
valves compared to healthy valves reflects cell signaling mechanisms and cellular 
processes that mediate the valve degeneration.   
Objective 1.1: To evaluate targeted protein abundance patterns of cell 
membrane receptors and ligands present in healthy and degenerative mitral 
valves. 
Hypothesis 2: Pathologic changes in degenerative mitral valves are mediated in part by 
endothelial to mesenchymal cell transformation (EndMT) and epidermal growth factor 
(EGF) signaling. 
Objective2.1: To identify spatial expression patterns by immunohistochemistry 
of differentially expressed proteins associated with EndMT and valve endothelial 
cell markers within the tissue matrix of healthy and degenerative mitral valves. 
Objective 2.2: To determine if EGF signaling molecules correlate spatially with 






Differential Protein Abundance in Healthy and Diseased Mitral Valve Tissue  
Degenerative mitral valve disease (DMVD), also known as myxomatous mitral valve 
disease, is widespread among dogs with prevalence as high as 58% of the population over eight 
years old52. It is also the most commonly seen cardiac disease in canines53. Indications such as a 
left-sided systolic heart murmur or mitral valve regurgitation as diagnosed by echocardiogram, 
along with predisposing factors such as advanced age, hypertension, or breed predisposition, 
provide strong evidence for the diagnosis of degenerative mitral valve disease. Breeds such as 
Cavalier King Charles Spaniels have been shown to have a genetic predisposition for developing 
DMVD both earlier and more frequently than other dogs,5 and studies have attempted to 
identify these breeds and understand what they have in common in order to narrow down 
genetic causes7.  The disease affects both humans and dogs and the degenerative valves from 
these species exhibit many histological similarities.  Because canine mitral valve disease has 
been shown to be a good model for studying human mitral valve degeneration3, and 
degenerative canine valves are more accessible than human valves,  examination of these 
samples can yield important insights into the cellular processes involved in the initiation and 
progression of DMVD.  
Multiple cell signaling pathways have been implicated in degenerative mitral valve 
disease, and cell membrane proteins play a key role in these cellular interactions. These 
signaling pathways likely mediate important cellular processes in degenerative mitral valves 
such as interstitial cell phenotype transformation, increases in cell density, and changes in 
extracellular matrix22. Cell phenotype transformation is the change from a normal interstitial 
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cell into an “activated myofibroblast” which has been shown to express catabolic enzymes 
implicated in the pathological remodeling process present in degenerative valves21. Cellular 
signaling mechanisms may be responsible for this transformation, and knowing the presence 
and magnitude of cell membrane proteins may help connect causes and effects in the disease 
process. Examples of signaling pathways that have been implicated in DMVD include TGFβ, 
serotonin, and developmental signaling processes17,31. However this disease process is complex 
and likely involves many interactive signaling pathways mediating intricate cellular processes.  
One approach to identifying other signaling cascades is to use a “systems biology” or “omics” 
approach to determine differential expression or abundance patterns between normal and 
diseased tissue.  Previous differential expression studies in canine degenerative MVD have 
included a differential transcriptomic study54 and a shotgun proteomic study22. These studies 
have provided important clues into cellular processes and associated signaling mechanisms that 
mediate disease progression. 
 The objective of this study was to further characterize cellular processes and signaling 
pathways in canine DMVD by using a targeted signaling protein array to compare protein 
abundance patterns of specific membrane receptors present in normal and degenerative mitral 
valves.  I hypothesized that the results of this study would provide further insight into complex 
cellular processes that mediate canine DMVD. 
Materials and Methods  
Septal mitral valve leaflets (n=3) were excised from deceased dogs with advanced 
DMVD presented to the CSU Veterinary Teaching Hospital necropsy facility. These samples, 
termed “degenerative” group, showed the characteristic signs of late-stage (Whitney grade 3) 
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degenerative mitral valve disease including large coalescing nodules, ruptured and elongated 
chordae tendinae, thickened and opaque valve leaflets, and a regurgitant jet “scar” or mark on 
the endocardium of the left atrium52. Normal septal mitral valve leaflets, termed “normal” 
group, were obtained from young healthy beagles sacrificed for other studies. Normal mitral 
valves (Whitney grade 0) were smooth, translucent, and thin. All samples were processed by 
first removing blood clots and other contaminants with repeated rinsing in phosphate buffered 
saline. Samples were then frozen at -80°C for storage. After thawing, samples were washed 
again with PBS and leaflets were cropped such that all samples were of similar weight by using 
a sensitive scale.  
To isolate the proteins from the raw valve tissue, the valves were minced to increase 
surface area and then digested with lysis buffer to break down the cells and release proteins 
from the rest of the cellular debris. Next they were centrifuged at 15000xg for 10 minutes, 
which isolated the protein containing supernate. A Modified Lowry protein assay was 
performed on the samples which involved the reaction of protein with cubric sulfate and 
tartrate resulting in the formation of tetradentate copper-protein complexes. The next step was 
the addition of Folin-Ciocalteu Reagent which was reduced in proportion to the chelated 
copper complexes. This produced a blue colored product measurable at 750nm. A known 
quantity of bovine serum albumin was diluted in lysis buffer at varying concentrations to 
produce the standard against which the unknowns were compared. 40µL of each standard and 
unknown sample were added to microplate wells, and 200 µL of Modified Lowry Reagent was 
then pipetted into each well. This mixture was incubated at room temperature for exactly ten 
minutes, and then 20 µL of Folin-Ciocalteu Reagent was added to each well. This was then 
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incubated at room temperature for thirty minutes and absorbance was measured using a 
spectrophotometer plate reader. The standard curve was obtained by plotting average values 
for the BSA standard against its concentration in mg/mL, and the curve was then used to 
determine protein concentration of the unknown samples. The protein concentrations from 
this assay were used to calculate the appropriate volumes needed to load equal masses of 
protein in the next procedure, the protein array. 
  The procedure for R&D Systems’ “Proteome Profiler” antibody array was followed, 
including loading of sample, adding and washing with particular buffers, antibodies, and 
fluorescence, and then obtaining images from the chemiluminescence imager. Reagents and 
samples were prepared according to the manufacturer’s specifications, and then the procedure 
was started using one diseased valve and one healthy valve. 2.0 mL of 1X array buffer was 
pipetted into each well of the 4-well multi-dish, this served as a blocking buffer. Tweezers were 
used to place the membranes in individual wells, and the container was incubated for one hour 
on a rocking platform shaker. 250 µg of sample was added to 300µL of array buffer and 
adjusted to obtain a final volume of 3 mL with array buffer. The array buffer was then removed 
from the wells and 1.5 mL of the prepared 3 mL sample mixture was added to both Part N and 
Part C of the multi dish. This was incubated overnight on ice with a rocking platform shaker. 
After incubation, each array was washed three times with 1X wash buffer for 10 minutes. For 
the part N array, 30 µL of detection antibody cocktail N was diluted to 1.5 mL with 1X array 
buffer and added to the well containing the N membrane. For the part C array, 30 µL of 
detection antibody cocktail C was diluted to 1.5 mL with 1X array buffer 8/1 and added to the 
well containing the C membrane. The membranes were then incubated for two hours at room 
26 
 
temperature on a rocking platform shaker. After incubation, each array was again washed three 
times with 1X wash buffer for 10 minutes. The Streptavidin-HRP was diluted in 1X array buffer, 
and 2 mL was added to each of the wells, covering the membrane. This was incubated on a 
rocking platform shaker for thirty minutes. After incubation, each array was washed three times 
with 1X wash buffer for 10 minutes. Following these last washes, 1mL of chemi reagent mix was 
pipetted onto each set of membranes.  Images of the membranes were then obtained using a 
chemiluminescence imager. After assessing the results, the procedure was repeated twice, for a 
total of three pairs of membranes for both the degenerative and normal group. Overall 6 valves 
were used, each valve generating two membranes, the Nonhematopoetic and Common 
Analytes arrays, and each of these had two spots per antibody tested leading to the collection 
of a large number of data points. 
After this, measurements of the spots that contained the 119 antibodies being tested 
were obtained on the computer image processing program ImageJ. Darker spots correlated to 
an increased level of antibody binding, and therefore a more positive result of protein 
expression. After quantifying the degree of visibility of the spots, they were normalized against 
IgM. This was a way of calibrating the sample loads by relating them to a housekeeping protein 
and positive control. Therefore, the different sample results could be compared. A Mann-
Whitney test was then used to determine the statistical significance of the differences between 
healthy and diseased samples for each protein. Healthy and diseased data points were also 




Valves were collected from three dogs with normal mitral valves and three dogs with 
degenerative mitral valves. The mitral valves used for the “normal” group of this study came 
from one year old beagles collected from a research facility. These animals underwent 
euthanasia for an orthopedic research project and no gross morphologic cardiac abnormalities 
were present. The valves used for the “degenerative” group were obtained from dogs 
euthanized for other health reasons. The first animal was a 15 year old male castrated Chow, 
the second a 13 year old male castrated Border Collie, and the third a 10 year old male 
castrated Greyhound. No animals were euthanized for the purposes of this study. The average 
age of the diseased group dogs was 12.7 and the average age of the healthy group was 1.  
The protein array revealed several proteins that had differential abundance between 
the groups. Most differences involved a protein having increased abundance in the diseased 
valves, while a few proteins were less abundant. (Figure 4.1) 
Based on the Mann Whitney statistical test and using a p value of .05, 25 proteins had 
significantly different abundance levels when comparing the two groups. The ratios of diseased 
to normal expression indicated that 18 proteins were increased, and a cutoff of twice the 
normal group’s average abundance level was considered biologically significant. (Table 4.1) 
Smaller differences were not considered biologically relevant. 
Integrin β3/CD61 was the most biologically significant protein among the proteins with a 
p value of less than 0.05. It had a ratio of 4.778 when comparing abundance of the 
degenerative group to the normal group. Integrin αv (the other half of the common integrin 
αvβ3 heterodimer) was measurable in 2 of the 3 diseased valves. However, because integrin αv 
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was undetectable in all normal valves, statistical significance could not be tested. Nevertheless, 
the presence of both parts of the heterodimer in the degenerative valves suggests that αvβ3 is 
the form of the integrin that is upregulated.  
Matrix metalloproteinase 2 (MMP-2) was found to have a p value of 0.003948 and 
biological significance of 2.4922 and was of interest because of the links found between it and 
integrin β347. Also, Matrix metalloproteinases or MMPs (a group of zinc requiring matrix 
degradation enzymes) have been previously shown to play a role in degenerative valve 
disease55. 
Other data of note from Table 1 include the related group of proteins Epiregulin, ADAM 
17, and HB-EGF, all with significant p-values and biological significance. Epiregulin and HB-EGF 
are both ligands for the epidermal growth factor receptor (EGFR). ADAM 17 is a regulator of 
these ligands; it is a membrane bound enzyme that when exposed to its substrate, such as Pro-







Figure 4.1 Representative Chemiluminescent Images Obtained from Protein Array 
Membranes 
The two membranes on the left were from a normal mitral valve, the two on the right from a 
degenerative one. The many dark spots on the degenerative Common Analytes Array 












Table 4.1 Differentially Abundant Signaling Proteins in Canine Normal and Degenerative 
Mitral Valves 
18 of 119 proteins tested were found to be statistically significant with a p value of <.05 when 
comparing the quantified protein expression of the two groups (degenerative and normal) with 












This protein array study indicated distinct protein differences between healthy mitral 
valves and those exhibiting signs of degenerative processes. The importance of these specific 
protein differences is still unknown, but understanding their relation to each other and known 
mechanisms active in degenerative disease yields interesting hypotheses.  
Integrin β3 was the most upregulated protein among all those studied. Integrins are 
heterodimeric integral membrane proteins with a variety of cellular functions. The most likely 
heterodimer for this protein to be a part of would be αvβ3 which has roles in cellular adhesion 
and migration and also influences TGFβ signaling by binding to its receptor on the cell surface42. 
TGF-β, a cytokine involved in ECM regulation, has been shown to have increased expression in 
degenerative valves18.  Integrin β3 has also shown to be upregulated in tissues where cells are 
undergoing transformative processes such as endothelial to mesenchymal cell transformation 
(EndMT)43-44. The presence of a high abundance of this protein in degenerative mitral valve 
tissue could have a few interpretations. Integrinβ3 may be mediating changes of the 
extracellular matrix that occur in diseased valves because it facilitates cellular movement, it 
may be contributing to cellular transformation by influencing TGFβ signaling, or it may simply 
be upregulated as a result of other transformative processes such as those affecting interstitial 
cells. Interstitial cells in degenerative mitral valve tissue undergo phenotype transformation, as 
shown by the expression of markers for smooth muscle cells21. This cellular type change could 
be responsible for some of the protein differences observed in this array. 
 Integrin αvβ3 is not widely expressed in normal tissues, but it is known to be increased 
in activated smooth muscle cells 56. The increase in myofibroblasts in degenerative mitral valve 
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tissue could account for this finding. Also there is evidence that cyclic strain induces increased 
levels of integrin αvβ3 in vascular smooth muscle cells57, which may have relevance to other 
findings where cyclic strain induced degenerative type change in canine mitral valves15.  
The upregulation of MMP-2 is consistent with prior data showing that catabolic matrix 
enzymes occur at a higher concentration in the diseased state of the mitral valve55. MMPs also 
generally correlate with disease progression, indicating that they play a role in facilitating the 
disease process, especially the dissolution of the stratification of the normal valve layers12. 
 The data showing an increased presence of HB-EGF, ADAM 17, and Epiregulin may have 
significance in our understanding of cell signaling in degenerative disease. HB-EGF and ADAM17 
are both important molecules involved in the development of mammalian heart valves, as 
shown by the results of mouse knockout models for both these proteins34,36,38.  When either of 
these molecules are absent in mutants, deposition of both GAG and collagen are increased. 
While this seems to be a paradoxical effect compared to our results of its increase in DMVD, it 
still underlies the importance of this signaling in the valve tissue and emphasizes it's 
involvement in valve homeostasis. The pathway including HB-EGF and ADAM 17 is a good 
example of a developmental pathway that initiates the EndMT process in early heart valve 
development35. Other developmental pathways have been implicated in degenerative mitral 
valve disease, such as BMP and Wnt signaling 29. Therefore, the increased abundance of these 
ligands (HB-EGF and Epiregulin) and their regulating enzyme(ADAM17) which activate the EGF 
receptor may be yet another dormant developmental pathway that is re-activated in the 
diseased state.  
33 
 
The large age difference between dog groups is a result of the samples that were 
available, and some protein expression changes could have been due to this age difference. 
However, degenerative valve disease is age-linked52, therefore it is difficult to age match when 
conducting these studies and so we acknowledge this possible confounding factor. 
In conclusion, the differently expressed proteins identified by this protein array are likely 
relevant to degenerative valve disease. Some identified proteins, like the significant expression 
of MMP-2, are consistent with previously described findings and therefore provide a degree of 
validation to the rest of the data. Other results, such as those of the EGF-related proteins, have 
not been previously identified in degenerative valves, but importantly are known to play roles 
in early developing valves such as the initiation of EndMT. This pattern of developmental 
pathway proteins increasing in abundance in degenerative valves has been previously reported, 
but not with these proteins specifically. The significantly increased abundance of integrin αvβ3 
is also a new finding with more than one possible interpretation, including phenotype 
transformation of interstitial cells to activated myofibroblasts, TGFβ signaling and EndMT. 
Therefore next steps of this study could include a more targeted examination of these proteins 
with the specific goal of examining their spatial relationship with known or previously unknown 








Cells in Degenerative Mitral Valve Tissue Undergo Endothelial to Mesenchymal 
Cell Transformation 
To understand the causes of degenerative mitral valve disease, it is important to 
investigate the changes and patterns occurring at the cellular level. The disease is characterized 
by increased expression of α smooth muscle actin (αSMA) in valvular interstitial cells (known as 
myofibroblast activation or transformation), an exuberant deposition of glycosaminoglycan 
(GAG), and a loss of proper valve architecture where the normally distinct layers of atrialis, 
spongiosa, and fibrosa become intermixed. This breakdown of cell layers contributes to valves 
becoming thickened, nodular, and less elastic, therefore leading to loss of mechanical integrity.  
Many mechanisms of this degradation of the extracellular matrix (ECM) have been 
identified, such as increased matrix metalloproteinases (MMPs) and changes in cellular activity 
resulting in overproduction of GAG. For instance TGFβ, a cytokine involved in ECM regulation, 
has been shown to have increased expression in diseased valves18. Also, specific areas of 
pathologic change visible on histological examination show phenotype transformation 
(myofibroblast activation) with increased cell density but not increased cell division.21  One 
possible explanation for increased cellular density is that cells may be migrating from other 
areas rather than simply dividing. Understanding why these areas have increased cell density in 
diseased valves could help explain the physical changes in degenerative valves, such as nodules 
and irregularities of valve stratification. Connecting these known observations with protein 
expression patterns reported in the previous chapter leads to a hypothesis that could explain 
cellular changes previously observed in degenerative mitral valve disease (DMVD). The 
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hypothesis of this study is that endothelial to mesenchymal cell transformation (EndMT), which 
is known to play a central role in heart valve development, is recapitulated in degenerative 
valve disease and could explain previous observations in degenerative valves such as increased 
density of myofibroblasts. 
EndMT is a multi-faceted process that takes place in wound healing, development 
(notably heart valve formation), and cancer progression. The process involves a cell receiving a 
signal to change phenotype after which it begins to lose characteristics that define it as an 
endothelial cell, such as adhesion molecules, and gain characteristics that define it as a 
mesenchymal cell. During this change, it detaches from the endothelial cells around it and 
migrates through the basement membrane into the tissue interstitum where it begins to 
express mesenchymal cell markers, which include αSMA25. To investigate if EndMT is occurring, 
two molecules were selected that should provide evidence that this cell migration pattern is 
present. The endothelial cell marker CD31, also known as platelet endothelial cell adhesion 
molecule-1, is a widely accepted marker of endothelial cells50.  Endothelial cells should normally 
only be present in a thin monolayer on the surface of heart valve tissues. If endothelial cells 
deviate from this pattern as shown by the indicator CD31, this would be evidence of endothelial 
cell migration into the interstitum, a critical step in EndMT.  
Myofibroblast transformation of interstitial cells, identified by αSMA expression, has 
been previously reported to occur in "cellular clusters" most often close to the atrialis surface 
of degenerative mitral valves. Co-localization of endothelial cell markers such as CD31 and/or 
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signaling molecules associated with EndMT with these cellular clusters could provide evidence 
for EndMT in the degenerative process.  
Much research has been done showing that the process of EndMT is involved in the 
development of the heart valve. By undergoing EndMT in the diseased state, the valvular cells 
may have reactivated dormant developmental pathways. Supporting this theory, other 
pathologic processes that mimic developmental pathways have been identified in diseased 
heart valves, including BMP and Wnt signaling29. The pathway including heparin binding 
epidermal growth factor (HB-EGF) and its sheddase, ADAM 17, is a good example of an 
essential developmental pathway that initiates EMT in early heart valve development as 
endothelial cells migrate and begin to form the cell layers and extracellular matrix of an adult 
valve35.  
The proteins HB-EGF and ADAM 17 were selected for examination because they were 
identified by a previous protein array as significantly increased in diseased valves, and because 
of their known role in EndMT. These proteins were examined for co-localization with 
myofibroblast transformation, identified by expression of αSMA, and migrating endothelial 
cells, identified by CD31. Co-localization of these proteins and cellular phenotype markers could 







Materials and Methods  
1. Tissue Collection 
Mitral valves were obtained post mortem from healthy dogs (N=8) and dogs considered 
to have DMVD (N=13). Valves were also obtained from 6 or 7 year old research beagles 
euthanized for another study and were confirmed to have normal mitral valve function by 
echocardiogram. The diseased valves were collected from dogs of various breeds that died or 
were euthanized for reasons unrelated to this study and underwent necropsy. These dogs were 
determined to have degenerative mitral valve disease by gross postmortem inspection of their 
valves, and were classified as either intermediate or severe. Valves and portions of papillary 
muscle and chordae tendinae were removed from the heart with surgical scissors and rinsed in 
phosphate buffered saline for approximately two hours. Valves were then sliced to fit in 
cassettes, fixed in 10% buffered formalin for 1-2 hours at room temperature, stored in 70% 
EtOH overnight, and embedded in paraffin blocks. 5µm slices were mounted on microscope 
slides for immunohistochemical staining. All valves were stained with Movat pentachrome stain 
(American Mastertech Scientific) and assessed for morphology to determine if microscopic 
degenerative changes were consistent with the gross examination and classification of the 
valves. 
2. Immunohistochemistry 
Slides were stained using immunohistochemistry to determine the location of 
endothelial cells and myofibroblasts and the activity of EGFR and integrin signaling. Endothelial 
cells were identified by positive staining for the marker CD31 (PECAM-1) (Dako, Carpenteria, 
CA, USA). Myofibroblasts were identified by α smooth muscle actin (αSMA) (Santa Cruz 
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Biotechnologies, CA, USA). The antigens HB-EGF (Santa Cruz Biotechnologies, CA, USA) and 
ADAM 17 (also known as TACE) (Sigma-Aldrich, St. Louis, MO, USA) were used to identify EGFR 
signaling, and integrin β3 (Abcam, Cambridge, MA, USA) was stained for as an indicator of cell 
migration and activation. To begin staining, slides were soaked in xylenes for 15 minutes for 
deparrafinization and rehydrated through graduated alcohol baths. Antigen retrieval was 
performed using a decloaking chamber at 95ºC for 40 minutes (Biocare Medical, Concord, CA, 
USA) and either citrate or pH 9 decloaking fluid (Target retrieval solution S1699, Dako). The 
slides were incubated with a background reducing agent (Biocare Sniper, Biocare Medical, 
Concord, CA, USA) for 5 minutes and then incubated with primary antibody overnight in a 
humidified chamber. Primary antibody was diluted at varying concentrations to obtain optimal 
staining balance (1:10 for CD31, 1:50 for HB-EGF, 1:200 for ADAM 17, 1:300 for Integrin β-3 and 
1:100 for αSMA). The following day, sections were blocked with peroxidase for 15 minutes 
followed by incubation with secondary antibody (Dako mouse HRP link) for 30 minutes. Slides 
were then stained with DAB+ chromagen and counterstained with hematoxylin (Dako) then 
dehydrated through graduated alcohol baths. Sections were rinsed with Tris-buffered saline 
containing .01% Tween 20 (TBS-T) between each step. The distribution patterns of the various 
proteins were reviewed and analyzed with light microscopy. 
3. Quantitative Analysis 
αSMA staining was quantified by counting the number of positive staining "cellular 
clusters" per histologic section of each whole valve. This excludes the normal thin layer of 
positive αSMA staining previously identified as smooth muscle cells close to the surface of the 
atrialis layer or actin staining of vessels or papillary muscle that may have been included in the 
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sample. It is defined by distinct staining of cells in a clumped or dispersed distribution extending 
into the spongiosa or fibrosa layers as described by Han 200823 and Disatian 200821. This 
abnormal staining is not seen often in healthy valves, but is clearly visible in degenerative valves 
such as shown in Figure 5.3. Differences between healthy, intermediate, and severe groups 
were compared with ANOVA and pairwise comparison tests.  
Semi quantitative analysis of cell staining for ADAM 17 and HB-EGF was assessed by 
assigning each sample a number 0-4 correlating to the approximate percentage of cells that 
stained positive in an average microscope field area of the valve tissue. The number correlates 
to percentages as follows: 0=no visible staining, 1= 1-25%, 2=26-50%, 3=51-75%, 4=76-100%. In 
this way the quantity of cells expressing each molecule can be assessed without taking into 
account stain intensity, which varies significantly among samples and batches of slides 
undergoing IHC. Results of staining between groups were compared using box plots and the 
Kruskall-Wallace test.  
CD31 and integrin β3 staining were observed by comparing photomicrographs obtained 
using the Axiocam camera and Axiovision software. Positive staining in areas of co-localization 
were identified and examined for evidence of cellular patterns. 
Results 
1. Animals 
Mitral valves were obtained post mortem from dogs (N=8) confirmed to have normal 
mitral valves by echocardiography and gross examination, and from dogs with degenerative 
mitral valve disease based on gross examination of their valves (N=11) or gross examination and 
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echocardiogram (N=2). The degenerative valve samples were sorted into two groups, 
intermediate (N=6) and severe (N=7), based on gross post mortem criteria. The degenerative 
valves were collected from dogs of various ages and breeds (see Table 5.1 and Figure 5.1) that 
underwent necropsy. The median age of dogs in the intermediate group was 11.5 years (range 
6 to 14). The median age of dogs in the severe group was 10 years (range 8 to 17). All dogs were 
either considered small dogs (<15 Kg) (N=13), or medium sized dogs (between 15 and 35 Kg) 
(N=8). The cause of death or euthanasia was mitral valve disease in one dog with severe 











Table 5.1 Breed and Gender of Sampled Dogs 
This table provides summary data of dogs whose mitral valves were sampled and studied. 
Breed and Gender of Dogs According to Group 
Control Gender Intermediate Gender Severe Gender 
Beagle F Beagle F Cavalier King Charles Spaniel M 
Beagle F Beagle M Miniature Poodle M 
Beagle F Border Collie M Mixed Breed F 
Beagle M English Spaniel F Australian Shepherd M 
Beagle M Mixed Breed F Beagle F 
Beagle M Pointer M Beagle M 
Beagle M   Labrador Retriever M 
Beagle M     
 








 Figure 5.1 Ages and Weights of Dogs  
The ages of the dogs included as diseased in this study were slightly higher than the ages of the 
control group. The weights of the dogs included in the diseased groups were also generally higher, but 














Movat staining of normal mitral valves showed a clear stratified structure consistent 
with previous studies. Atrialis, spongiosa, and fibrosa layers were identifiable and nodules and 
valve thickening were absent. Intermediate stage valves showed some disorganized black 
elastin fibers in the spongiosa layer as well as less distinct staining of the yellow collagen areas 
in the fibrosa. Severely diseased valves showed substantially increased amounts of GAG 
staining as well as  loss of valve stratification, especially towards the distal end of the leaflet. 
(Figure 5.7 A-C) 
3. Immunohistochemistry  
αSMA staining was found in all mitral valves stained, but the distribution and amount of 
positive cells varied between the groups. Normal mitral valves had minimal evidence of positive 
αSMA  myofibroblast clusters. The mean number of myofibroblast clusters per histologic 
section of the normal, intermediate degenerative, and severe degenerative groups were 1.13, 
3.17, and 6.86 respectively. Statistical analysis showed that all groups were significantly 
different (Table 5.2). αSMA stained myofibroblasts were generally present near the atrial 
surface and towards the endothelium of the normal valves in a smooth, coherent pattern 
(Figure 5.3 A). In intermediate degenerative valves, myofibroblast type cells identified by 
positive αSMA staining were more often present in deeper valve layers, but were generally 
dispersed and evenly distributed compared to the severe valves. The severe valves often 
exhibited aggregates of αSMA near the valve surface (Figure 5.6 C), and streaks originating at 
the surface and descending into the interstitum (Figure 5.5 C).These streaks co-localized with at 
least one other of our molecules of interest in nearly all cases, and often co-localized with most 
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of them (Figures 5.5 and 5.6). Also, αSMA staining was very prevalent and widespread 
throughout all valve layers in some of the diseased valves (Figure 5.3 C). 
Positive CD 31 staining was found on sections of the endothelium of most normal and 
intermediate-stage valves and all severely degenerative valves. This staining was usually 
present on involutions or folds of the valve tissue, and was also present in blood vessel walls in 
papillary muscle sections, showing normal endothelial cell staining. Many edges of the valve 
tissue did not stain well for CD31 which may have been due to loss of the surface endothelial 
cells during tissue processing. In many intermediate and all but one severe group valve, CD31 
staining was also found in deeper layers of the valve, and positive cells appeared to be 
descending into the atrialis and spongiosa layers (Figure 5.2 B and Figure 5.3 E and F). These 
positive CD31 areas did not exhibit visual characteristics of capillaries or immune cells, which 
would be possible explanations for their location. This staining was usually present on areas 
specifically identified as degenerative based on Movat staining most often co-localized with 
αSMA positive myofibroblast clusters.  
Cells positive for HB-EGF were found in all mitral valves and the staining was widely 
distributed in most samples. Although not significantly increased in the diseased valve groups 
when analyzed with a Kruskall-Wallis test, the amount of HB-EGF staining showed a clear 
upward trend compared to the healthy valves as presented in Figure 5.4. HB-EGF often stained 
more heavily in areas of αSMA myofibroblast staining and areas of increased cellular density 
(Figure 5.6 B), but did not clump like CD 31 or αSMA. It did however form streaks similar to 
CD31 as shown in Figure 5.5 (B) and co-localized with ADAM 17 both at the surface of valves 
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and deeper within the matrix (Figure 5.7). HB-EGF positive streaks were found in the middle 
layer of many healthy valves (Figure 5.7 G). ADAM 17 staining was usually found in a pattern 
similar to that of HB-EGF. That is, staining was often widespread and no “clumping” was found, 
however staining was increased in severely degenerative valves compared to normal valves 
(Figure 5.4) and in areas that appeared to have active cellular change occurring such as in Figure 
5.7. Also, the molecule integrin β3 was detected in many abnormal locations on the diseased 












Table 5.2 P Values for α-Smooth Muscle Actin Staining of Normal, Intermediate Degenerative and 
Severely Degenerative Mitral Valves : After the one way ANOVA indicated that the data were from 
different distributions (P value= .00000825), pairwise comparisons using Student's t tests with pooled 
standard deviation were conducted. This table shows p values for comparisons of the three groups. 
 Healthy Intermediate 
Intermediate p=0.03035  
Severe p=0.0000019 p=0.00064 
 














Figure 5.2 Immunohistochemistry for CD31 of Canine Mitral Valves  
Photomicrograph A is a high power view of endothelial cells (black arrow) on a normal area of mitral 
valve. These cells are squamous shaped, regular, and have clear boundaries and nuclei. Photo B shows 
a degenerative area of mitral valve where an irregularity on the valve surface (brown lump) has 
stained positive for CD31. These cells are rounder, bunched, and have abnormal shapes compared to 
the cells in A. The area adjacent to the abnormality appears to lack normal endothelial cells. CD31 
staining in cells below the surface was also evident (orange arrow). This cell is unlikely to be a 
macrophage which also expresses CD31 because these cells are rarely found in degenerative mitral 






 Figure 5.3 αSMA and CD31 Immunohistochemistry of Normal, Intermediate Degenerative, and 
Severely Degenerative Canine Mitral Valves 
Photomicrographs of sequential tissue sections of normal (A, D), intermediate degenerative (B,E), and 
severely degenerative (C, F) mitral valves stained for αSMA (A-C) or CD31(D-F). Brown staining 
indicates the presence of the target molecule, while purple shows the hematoxylin counter stain. 






Figure 5.4  Semi Quantitative Analysis of HB-EGF and ADAM17 Immuno-Staining of Normal, 
Intermediate Degenerative, and Severely Degenerative Mitral Valves 
HB-EGF and ADAM 17 were both detected on most valves stained. HB-EGF shows an increase in 
staining in the intermediate and severe groups, while ADAM 17 only had increased staining in the 




 Figure 5.5 Immunohistochemistry of Sequential Sections of a Severely Degenerative Mitral Valve 
Stained for CD31 (A), HB-EGF (B), αSMA (C), and Movat Pentachrome (D).  
Brown staining on A shows CD 31 present on the endothelium progressing deeper into the valve 
matrix from left to right. HB-EGF and αSMA are also present in this area, and the blue staining of GAG 
found in D as well as the whorled pattern of the interstitial cells indicates that below this area is more  
evidence of degenerative disease. For Movat staining, collagen = yellow, glycosaminoglycan = blue, 
elastin = black. From right to left, the disruption of the black elastin layer of the atrialis is also an 







Figure 5.6 Immunohistochemistry of Sequential Sections of a Severely Degenerative Mitral Valve 
Stained for CD31 (A), HB-EGF (B), αSMA (C), and Integrin β3 (D). 
 Positive staining of this area (dark brown) indicates co-localization of these molecules of interest. 












Table 5.3 Semi Quantitative Analysis of HB-EGF and ADAM 17 Immunohistochemistry Staining in 
Canine Mitral Valves 
 HB-EGF ADAM 17 
Healthy group mean 1.88 2.00 
Intermediate group mean 2.67 1.83 
Severe group mean 2.43 3.00 
Kruskal-Wallis test p value 0.2036 0.1683 
 









Figure 5.7 Movat (A-C), ADAM 17(D-F), and HB-EGF(G-I) Immuno-Staining of Normal(A,D,G), 
Intermediate Degenerative (B,E,H), and Severely Degenerative(C,F,I)Mitral Valves.  
For Movat staining, Collagen = yellow, Glycosaminoglycan = blue, elastin = black. Clear layers are 
visible in A, less distinct in B, and nonexistent in C which has distinct blue GAG buildup. D has minimal 
positive brown staining, while the presence of ADAM17 is markedly increased on the surface of E and 
deeper in the matrix of F. HB-EGF appears to be present in organized streaks in G. In both H and I 









As reported previously, degenerative mitral valves exhibited cellular clusters of αSMA 
positive interstitial cells consistent with myofibroblast transformation. Although not quantified 
in this study, these abnormal areas subjectively had higher cell density compared to the 
surrounding tissue and compared to normal mitral valves. Other studies have not been able to 
identify evidence of active cell division based on sparse staining of the marker of active dividing 
cells, Ki6721,49,58. Therefore, a mechanism for increased cellular density has not yet been 
identified.  
As expected the cells on the valve surface were positive for the endothelial cell marker, 
CD 31. Many valves showed areas of negative staining for CD31 on the valve surface consistent 
with denudation of the endothelium.  It is not clear from this study whether endothelial 
denudation was an ante-mortem pathological change or a post-mortem artifact associated with 
valve processing.  The fact that both normal and degenerative valves showed evidence of 
endothelial denudation is more supportive of the latter interpretation.  An important finding of 
this study was the presence of CD31 positive cells deep within the valve interstitum of 
degenerative mitral valves.  These CD31 positive cells were not associated with vessels.  This 
finding supports the presence of endothelial cells that have migrated into the valve interstitum 
and provides evidence that EndMT is occurring in degenerative mitral valves. As interstitial 
CD31 positive cells were strongly associated with areas of high cell density myofibroblasts 
further supports EndMT and provides a possible mechanism for the increase in cellular density 
in these areas.  
55 
 
Interstitial CD 31 staining was more often seen in severely degenerative valves than in 
intermediate valves or normal valves, but was still found in some of these samples. This 
suggests that EndMT could be an early cellular change in the disease process which progresses 
with severity.  
ADAM17, HB-EGF, and integrin β3 all showed increased staining in degenerative valves 
compared to normal valve samples. While it is difficult to specify the extent to which each of 
these proteins affects degenerative valve disease, understanding the roles that they are known 
to play in cell interactions yields some interesting possible explanations which support the 
EndMT hypothesis.  
The co-localization of CD31 and other proteins targeted such as HB-EGF, ADAM 17, 
Integrin β3, and αSMA provides further evidence that EndMT is occurring. First, αSMA staining 
identifies areas of cellular transformation where myofibroblasts become clumped and descend 
into deeper cell layers beneath the atrialis 21. This cellular activity is a possible result of EndMT. 
Next, the presence of integrin β3 in these areas as either a marker of cellular migration or a 
product of activated smooth muscle cells 56,59 further indicates cellular phenotype 
transformation. In addition to these markers, the cell signaling proteins HB-EGF and ADAM 17 
present a possible initiating signal for EndMT. These proteins have previously been identified in 
EndMT in mitral valve development 34,36,60 and therefore the possibility of reactivating their 
signaling in the diseased state seems reasonable.  
It is unknown if activated EGFR signaling interacts with other possible initiators of 
EndMT, like TGFβ signaling. Both of these receptors are influenced by integrins, and TGFβ’s 
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receptor requires modulation of integrin β3 to induce EndMT42. In addition, the non-canonical 
pathway of TGFβ signaling has the same cellular reaction as EGFR signaling, that is the 
activation of ERK1/2 and subsequent production of MMPs26. Also, if TGFβ is initiating EndMT in 
degenerative mitral valves, increased levels may be cause by serotonin signaling (Figure 2.2).  
While some of the demographics of the dogs used in this study varied between groups, 
such as the dog weights and ages, effort was made to choose samples which were similar to the 
control group to minimize the chance of differences being the consequence of size, age, and 
breed variability. Because of this, the valves should be reasonably comparable and histological 
differences should be attributed to the valves' disease state. Also, 14 of the 21 dogs used in this 
study belonged to breeds designated as having a higher risk of MMVD by Table 1 from a study 
by Parker et al. 7. Therefore most disease changes in the sample valves should be consistent 
with previously described canine DMVD.  
In conclusion this study demonstrated that cells expressing the endothelial marker CD31 
are present beneath the normal surface layer in both clumps and individual cells in 
degenerative valves. This finding suggests that endothelial cells have migrated into the valve 
interstitum in a pattern resembling the EndMT process apparent in developing valves and 
provides the first evidence of EndMT in mitral valve degeneration. This process could explain 
the increased cellular density in degenerative areas on mitral valves EndMT in degenerative 
mitral valves may be influenced by integrin β3 or may be initiated, as in the developing valve, 





 Conclusions and Future Directions  
Results of the above studies highlight the relevance of certain signaling molecules and 
cell markers in degenerative mitral valve tissue. While searching for an explanation for the 
areas of increased cell density in degenerative valves described in previous literature, the 
hypothesis of cellular movement and migration from specific signaling patterns was generated. 
The array of signaling proteins provided a baseline for the investigation of molecules that had 
significance to DMVD, and analysis of these proteins' functions helped support the theory that 
EndMT contributes to the areas of increased cell density. The notably increased abundance of 
the molecule integrin αvβ3 supported the hypothesis of cell movement and migration because 
it is upregulated in actively moving cells, and it has also been described to be upregulated in 
EMT. The array also revealed molecules whose increased abundance could be responsible for 
altered signaling in degenerative valves. These molecules, the EGFR ligand HB-EGF and its 
partner molecule ADAM17, have known roles in EndMT in early developing valves, and 
therefore support another theory of DMVD, that of the recurrence of developmental pathways 
in the degenerative process.   
The immunohistochemical study results show a more complete picture of where 
endothelial cells are located in normal and degenerative valves as well as their relationship to 
activated myofibroblasts. This information shows a direct correlation between endothelial cells 
migrating into the interstitum via EndMT and areas of increased cell density populated by 
αSMA positive myofibroblasts. Therefore the structural change of abnormal cell clusters typical 
of degenerative valves appears to be caused, at least in part, by EndMT. While EndMT is a 
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complex process that could be initiated by many different mechanisms, the co-localization of 
HB-EGF and ADAM17 with these degenerative areas indicates that the EGFR signaling cascade 
plays a role.  
This study provides first evidence of EndMT in degenerative mitral valve disease. 
However, this information seems to bring up more questions than it answers. For example, 
what is the temporal relationship between EndMT and the structural changes that occur in 
diseased valves? Does it originally contribute to nodule formation or is it a healing and 
remodeling attempt by the tissue as a result of increased strain on the valve  after it has already 
degenerated and developed a regurgitant leak? Also, perhaps most importantly, can it be 
altered by blocking signaling to slow degenerative valve changes? 
All these important questions have the potential to be answered in future experiments. 
Future studies should start with the staining of cells with both αSMA and CD 31 with different 
indicator colors. This would serve as more definitive evidence that cells are transforming 
because they would be expressing both endothelial and mesenchymal markers.  If samples 
could be compared to the timeline of DMVD more definitively with additional history of the 
progression of valve disease in the patients such as echocardiograms of all the animals, it could 
provide more indications of how soon EndMT is happening after degeneration starts.  
Next, using a method such as lineage tracing would be a way to track the movement of 
individual cells while they are still alive in tissue culture and determine how quickly EndMT 
happens in valves. Variables that influence EndMT could be modified, and their effects 
quantified. In this way HB-EGF could be tested to determine if increasing its concentration or 
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that of ADAM17 has a positive effect on EndMT, further supporting the hypothesis presented 
above that it is a primary initiator of the mechanism in DMVD. Monoclonal antibodies that 
block EGF signaling by not allowing HB-EGF to bind could also be used to sort through the 
causes and effects of these signaling processes.  
In addition to these proposed studies, an experiment using an inducible model of DMVD 
such as a cyclic valve stretcher could be performed with the goal of determining if strain 
induces EndMT and if so, which molecules initiate it. This would provide valuable information 
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